Carotegrast methyl Cmax (ng mL-1) Estimated ratio after inverse logarithmic conversion* 2.08
90% CI of the ratio 1.54, 2.80
p-value** 0.0005
AUC0-t (ng h mL-1) Estimated ratio after inverse logarithmic conversion* 2.02
90% CI of the ratio 1.53, 2.67
p-value** 0.0004
Tmax (h) Median (Min, Max) in carotegrast methyl alone 1.0 (0.5, 4.0)
Median (Min, Max) in the combination with rifampicin 2.0 (0.5, 4.0)
Test statistics 18.5
p-value** 0.2847
t1/2 (h) Estimated ratio after inverse logarithmic conversion* 1.35
90% CI of the ratio 1.12, 1.63
p-value** 0.0112
MRT0-t (h) Estimated ratio after inverse logarithmic conversion* 1.05
90% CI of the ratio 0.98, 1.14
p-value** 0.2594
Carotegrast Cmax (ng mL-1) Estimated ratio after inverse logarithmic conversion* 4.78
90% CI of the ratio 3.64, 6.29
p-value** <.0001
AUC0-t (ng h mL-1) Estimated ratio after inverse logarithmic conversion* 5.59
90% CI of the ratio 4.60, 6.79
p-value** <.0001
Tmax (h) Median (Min, Max) in carotegrast methyl alone 2.0 (1.0, 4.0)
Median (Min, Max) in the combination with rifampicin 4.0 (2.0, 4.0)
Test statistics 27.5
p-value** 0.0020
t1/2 (h) Estimated ratio after inverse logarithmic conversion* 0.75
90% CI of the ratio 0.58, 0.97
p-value** 0.0677
MRT0-t (h) Estimated ratio after inverse logarithmic conversion* 1.13
90% CI of the ratio 1.04, 1.22
p-value** 0.0164
M-I Cmax (ng mL-1) Estimated ratio after inverse logarithmic conversion* 1.42
90% CI of the ratio 1.15, 1.75
p-value** 0.0094
AUC0-t (ng h mL-1) Estimated ratio after inverse logarithmic conversion* 1.58
90% CI of the ratio 1.30, 1.92
p-value** 0.0007
Tmax (h) Median (Min, Max) in carotegrast methyl alone 1.0 (0.5, 2.0)
Median (Min, Max) in the combination with rifampicin 1.0 (0.5, 4.0)
Test statistics 37.0
p-value** 0.0348
t1/2 (h) Estimated ratio after inverse logarithmic conversion* 0.89
90% CI of the ratio 0.70, 1.13
p-value** 0.3877
MRT0-t (h) Estimated ratio after inverse logarithmic conversion* 1.09
90% CI of the ratio 1.01, 1.19
p-value** 0.0750
M-II Cmax (ng mL-1) Estimated ratio after inverse logarithmic conversion* 3.57
90% CI of the ratio 2.91, 4.38
p-value** <.0001
AUC0-t (ng h mL-1) Estimated ratio after inverse logarithmic conversion* 6.05
90% CI of the ratio 5.13, 7.14
p-value** <.0001
Tmax (h) Median (Min, Max) in carotegrast methyl alone 2.0 (1.0, 4.0)
Median (Min, Max) in the combination with rifampicin 4.0 (2.0, 6.0)
Test statistics 51.5
p-value** 0.0010
t1/2 (h) Estimated ratio after inverse logarithmic conversion* 0.70
90% CI of the ratio 0.63, 0.78
p-value (Treatment Group) <.0001
MRT0-t (h) Estimated ratio after inverse logarithmic conversion 1.49
90% CI of the ratio 1.41, 1.57
p-value** <.0001
Carotegrast-glu Cmax (ng mL-1) Estimated ratio after inverse logarithmic conversion* 0.79
90% CI of the ratio 0.67, 0.94
p-value** 0.0272
AUC0-t (ng h mL-1) Estimated ratio after inverse logarithmic conversion* 1.14
90% CI of the ratio 0.99, 1.30
p-value** 0.1158
Tmax (h) Median (Min, Max) in carotegrast methyl alone 2.0 (1.0, 4.0)
Median (Min, Max) in the combination with rifampicin 2.0 (1.0, 4.0)
Test statistics 11.0
p-value** 0.1719
t1/2 (h) Estimated ratio after inverse logarithmic conversion* 0.98
90% CI of the ratio 0.84, 1.14
p-value (Treatment Group) 0.7938
MRT0-t (h) Estimated ratio after inverse logarithmic conversion 1.35
90% CI of the ratio 1.26, 1.44
p-value** <.0001